MSIF; the Multiple Sclerosis Internal Federation has been asking since 2019 the World Health Organisation to add 3 MS treatments (multiple sclerosis). To its list of essential treatments. But what do all these MSIF and essential treatment lists of WHO actually mean? Don’t worry we will go through all of these terms as clearly as possible.
Table Of Content
- What Is MSIF?
- What Is The WHO Vital Drug Treatments Listing And Why Is It Important?
- MSIF’s Recommendation To Add 3 MS Treatments
What Is MSIF?
The Multiple Sclerosis International Federation is a one-of-a-kind worldwide network of Multiple Sclerosis organizations, persons with MS, volunteers, and employees from all over the world. The only aim of the organization is to get rid of these diseases from the roots worldwide and find effective MS treatment.
It is a condition that directly affects the central nervous system more specifically the brain and the spinal cord.
When one suffers from MS, the immune system assaults the protective coating called myelin which protects nerve fibers, causing communication issues between the brain and other parts of the body. Ultimately, the condition might result in irreversible nerve fiber loss or degeneration.
According to the MSIF, around 2.8 million people are suffering from the unfortunate disease. So the organization is constantly working on ways to find MS treatment and create awareness among the people so more people can serve the cause.
Check out the medicscales popular ED pills like Vidalista 80 or Vidalista 60 with exciting deals and offers.
What Is The WHO Vital Drug Treatments Listing And Why Is It Important?
EML or Essential Medicines List is a registry of the minimal medicine requirements for each healthcare system. All of those medicines mentioned in the list must be provided at the cost decided by WHO so that the poor class and middle-class people can afford them. EML plays an important role in ensuring worldwide medication availability.
The treatments or medicines for the disease decided are the ones that are widely prevalent in the world. For instance inhalation medication, local anesthetics, medical gases, opioid analgesics, Intestinal anthelminthic and etc.
FDA Approved pills For Men’s Well-Being
Super Tadapox
Super p force
Sildalist
MSIF’s Recommendation To Add 3 MS Treatments
MSIF is pushing for three disease-modifying therapies (DMTs) to be included in the World Health Organization’s (WHO) essential medicine list in order to ensure equitable availability of MS treatments globally.
The three disease-modifying therapies(DMTs) awaiting approval are;
- Rituximab
- Mavenclad(Cladribine)
- Glatiramer acetate(Capoxane)
This MSIF has been asking WHO since 1999 but now finally the EML committee has considered as MS cases are increasing substantially and that MS treatment is still lacking.
The committee is all set to convene from April 24 to 28, 2023, to evaluate all submissions, and we hope to know the results by June 2023.
Adding DMTs to the WHO Essential Medicine List is simply another way to improve the availability of MS treatment. However, the organization will continue to fight to ensure that anyone suffering from MS has access to inexpensive treatment, particularly in steep communities.
